NCT02877264View on ClinicalTrials.gov

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Conditions
Healthy
Interventions
DRUG

vapendavir 132 mg capsule

DRUG

vapendavir 264 mg tablet

DRUG

vapendavir 24 mg/mL oral suspension

Trial Locations (1)

55114

Aviragen Investigational Site, Saint Paul

Sponsors
All Listed Sponsors
lead

Aviragen Therapeutics

INDUSTRY

NCT02877264 - A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers | Biotech Hunter | Biotech Hunter